A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (NCT04770896)
A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.
Who can join: Review the eligibility criteria below.
Location: Medizinische Universität Innsbruck — Innsbruck
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (124 Sites)
Showing the first 25 of 124 sites.
- Medizinische Universität Innsbruck — Innsbruck,
- Uniklinikum Salzburg, LKH — Salzburg,
- Universitätsklinikum St. Pölten — Sankt Pölten,
- Klinik Favoriten — Vienna,
- AZ KLINA — Brasschaat,
- Hospital Erasme — Brussels,
- Cliniques Universitaires St-Luc — Brussels,
- UZ Leuven — Leuven,
- AZ Delta (Campus Rumbeke) — Roeselare,
- Hospital Felicio Rocho — Belo Horizonte, Minas Gerais
- Hospital Moinhos de Vento — Porto Alegre, Rio Grande do Sul
- Hospital Sao Lucas - PUCRS — Porto Alegre, Rio Grande do Sul
- Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN — Florianópolis, Santa Catarina
- Clinicas Oncologicas Integradas - COI — Rio de Janeiro,
- Beneficencia Portuguesa de Sao Paulo — São Paulo,
- Multiprofile Hospital for Active Treatment Uni Hospital — Panagyurishte,
- Complex Oncological Center - Plovdiv, EOOD — Plovdiv,
- Arthur J.E. Child Comprehensive Cancer Center-Calgary — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- Juravinski Cancer Centre — Hamilton, Ontario
- Princess Margaret Cancer Center — Toronto, Ontario
- Hunan Cancer Hospital — Changsha,
- Fujian Provincial Hospital — Fuzhou,
- The First Affiliated Hospital, Sun Yat-sen University — Guangzhou,
- Nanfang Hospital, Southern Medical University — Guangzhou,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Unresectable Hepatocellular Carcinoma
- Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients — Los Angeles, California
- Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells — Basking Ridge, New Jersey
- An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery — Baltimore, Maryland
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCC — Boston, Massachusetts
Explore by condition: All Unresectable Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.